Key result
Transdermal scopolamine increased vagal activity in patients with congestive heart failure, evidenced by a 5.5% increase in mean RR interval (P<.001) and a 45% increase in its SD (P<.001).
Why the study?
Does transdermal scopolamine increase vagal activity as assessed by heart rate variability in patients with moderate to severe congestive heart failure?
Does transdermal scopolamine increase vagal activity as assessed by heart rate variability in patients with moderate to severe congestive heart failure?
p-value: p=<.001
Transdermal scopolamine increases vagal activity, as measured by heart rate variability, in a subset of patients with moderate to severe heart failure.
No takes yet. Share an insight, caveat, or question.
May support vagal modulation trials in heart failure; leaves open clinical benefit and requires randomized confirmation.
Rovere et al. (1994) studied moderate to severe congestive heart failure (n=21). transdermal scopolamine vs. baseline was evaluated on Heart rate variability (mean RR interval and its SD) (p=<.001). Transdermal scopolamine increased vagal activity in patients with congestive heart failure, evidenced by a 5.5% increase in mean RR interval (P<.001) and a 45% increase in its SD (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: